PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsNadide
Nadide
Nadide is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
adstiladrinBiologic Licensing Application2024-08-12
corgardNew Drug Application2023-07-21
detijian nadhunapproved drug other2022-02-21
enbrace hrunapproved drug other2023-12-15
enlyteunapproved drug other2022-07-01
nadololANDA2024-07-30
nadolol and bendroflumethiazideANDA2016-04-15
paxlyteunapproved drug other2024-08-01
wal-nadol pmOTC monograph not final2023-09-13
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
550 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———41——1648
Covid-19D000086382—U07.17631420
Diabetes mellitusD003920HP_0000819E08-E139321418
HypertensionD006973EFO_0000537I105212414
Breast neoplasmsD001943EFO_0003869C5031—1813
InfectionsD007239EFO_0000544—4123312
Type 2 diabetes mellitusD003924EFO_0001360E115111311
AgingD000375GO_0007568R41.81—3—148
PoliomyelitisD011051EFO_0007450A804231—8
CarcinomaD002277—C80.031—116
Show 36 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B201611—219
LymphomaD008223—C85.91261——15
DyslipidemiasD050171HP_0003119—10—2——12
SyndromeD013577——241—39
Hepatitis cD006526—B19.2343—19
HepatitisD006505HP_0012115K75.9263—19
Prostatic neoplasmsD011471—C61431—29
Hepatitis aD006506EFO_0007305B15263——8
Multiple myelomaD009101—C90.0431—18
Colorectal neoplasmsD015179——3—1—37
Show 40 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C802512——433
LeukemiaD007938—C9575———10
DepressionD003863—F33.9—1——910
Stomach neoplasmsD013274EFO_0003897C1621——68
Non-small-cell lung carcinomaD002289——83———8
Pancreatic neoplasmsD010190EFO_0003860C2551——38
Cognitive dysfunctionD060825HP_0001268G31.8422——68
Heart failureD006333HP_0001635I5034——38
Lung neoplasmsD008175HP_0100526C34.9047———7
Depressive disorderD003866EFO_1002014F32.A—1——67
Show 88 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acquired immunodeficiency syndromeD000163EFO_0000765B207————7
GlioblastomaD005909EFO_0000515—5————5
Head and neck neoplasmsD006258——2———35
PregnancyD011247EFO_0002950Z33.14————4
HyperlipidemiasD006949HP_0003077E78.54————4
MelanomaD008545——2———24
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.91———34
Uterine cervical neoplasmsD002583HP_0030159—2———24
T-cell lymphomaD016399——3————3
Follicular lymphomaD008224—C823————3
Show 102 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Sleep initiation and maintenance disordersD007319—F51.01————1111
Chronic painD059350HP_0012532—————55
Mental disordersD001523EFO_0000677F91.9————44
Post-traumatic stress disordersD013313EFO_0001358F43.1————44
StrokeD020521EFO_0000712I63.9————44
Chronic diseaseD002908——————44
Heart diseasesD006331EFO_0003777I51.9————33
Bipolar disorderD001714EFO_0000289F30.9————33
Mitochondrial myopathiesD017240Orphanet_206966G71.3————33
Psychotic disordersD011618—F20.81————33
Show 175 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNadide
INNnadide
Description
Nicotinamide adenine dinucleotide (NAD) is a coenzyme central to metabolism. Found in all living cells, NAD is called a dinucleotide because it consists of two nucleotides joined through their phosphate groups. One nucleotide contains an adenine nucleobase and the other, nicotinamide. NAD exists in two forms: an oxidized and reduced form, abbreviated as NAD+ and NADH (H for hydrogen), respectively.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c1
Identifiers
PDB—
CAS-ID53-84-9
RxCUI—
ChEMBL IDCHEMBL1234613
ChEBI ID44215
PubChem CID925
DrugBankDB00157
UNII ID0U46U6E8UK (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 65 documents
View more details
Safety
Black-box Warning
Black-box warning for: Enlyte
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
17 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use